[Activity of lysozyme in serum and selected granulocytic cytoenzymatic markers evaluated in patients with duodenal ulcer treated with ranitidine].
In 20 patients with active, endoscopically confirmed duodenal ulcer, serum lysozyme activity, metabolic and phagocytic activity of neutrophils using the NBT spontaneous and stimulated test and stimulated test, and cytoenzymatic reaction for alkaline phosphatase were evaluated before treatment and after two weeks of treatment with ranitidine 150 mg every 12 hours. In some of the studies carried out the differences were obtained between the mean results which turned out to be statistically significant. In the group of patients with duodenal ulcer after two weeks of treatment with ranitidine, a statistically significant increase was found of diluted serum lysozyme activity as compared to the activity of this enzyme before the treatment. After the treatment with ranitidine, a statistically highly significant increase was noted of alkaline phosphatase activity in the neutrophils as compared to the activity of this enzyme assessed in patients with untreated duodenal ulcer. On the basis of the obtained results of studies the conclusions were formulated: 1) The increase of diluted serum lysozyme activity in the patients with duodenal ulcer after two weeks of treatment with ranitidine may evidence the presence of inhibitors of the enzyme in the serum of the studied group. 2) In patients with duodenal ulcer after two weeks of treatment with ranitidine the activity increases of cytoenzymatically determined alkaline phosphatase in the neutrophils, while the cytoenzymatically determined values of the markers in the test with NBT remain unchanged.
II Katedry i Kliniki Chorób Wewnetrznych Sl. Ak. Med.
A
A
Hrycek
J
J
Dabek
H
H
Zielińska-Stasiura
B
B
Kłaptocz
M
M
Nowakowska
H
H
Radosz-Komoniewska
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood*; D009504:Neutrophils / Q000201:enzymology; D011899:Ranitidine / Q000627:therapeutic use*
D015415:Biomarkers; D011899:Ranitidine; D009113:Muramidase
Aktywność lizozymu w surowicy i wybrane granulocytarne wskaźniki cytoenzymatyczne oceniane u chorych z wrzodem dwunastnicy leczonych ranitydyna.